References
- Balch CM, Gershenwald JE, Soong SJ, et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–206
- Basile JR, Czerninski R. (2010). The role of CIP2A in oral squamous cell carcinoma. Cancer Biol Ther 10:700–2
- Böckelman C, Hagström J, Mäkinen LK, et al. (2011). High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 104:1890–5
- Chen KF, Liu CY, Lin YC, et al. (2010). CIP2A mediates effect of Bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29:6257–66
- Côme C, Laine A, Chanrion M, et al. (2009). CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15:5092–100
- Dennis LK. (1999). Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 135:275–80
- Dong QZ, Wang Y, Dong XJ, et al. (2011). CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18:857–65
- Fang Y, Li Z, Wang X, Zhang S. (2012). CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol 33:2299–306
- He H, Wu G, Li W, et al. (2012). CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 21:143–9
- Huang LP, Adelson ME, Mordechai E, Trama JP. (2011). CIP2A expression is elevated in cervical cancer. Cancer Biomark 8:309–17
- Huang P, Qiu J, You J, et al. (2012). Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers 5:422–9
- Junttila MR, Puustinen P, Niemela M, et al. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130:51–62
- Junttila MR, Westermarch J. (2008). Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7:592–6
- Lee J, Park EJ, Hwang JW, et al. (2011). CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol Int 32:2023–30
- Li W, Ge Z, Liu C, et al. (2008). CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14:3722–8
- Lin YC, Chen KC, Chen CC, et al. (2012). CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinomacells. Oral Oncol 48:585–93
- Liu CY, Shiau CW, Kuo HY, et al. (2013). Cancerous inhibitor of protein phosphatese 2A determines Bortezomib-induced apoptosis in leukemia cells. Haematologica 98:729–38
- Ren J, Li W, Yan L, et al. (2011). Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer 105:1905–11
- Seth A, Watson DK. (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41:2462–78
- Seth A, Catzavelos C, Vary C, Ascione R. (2001). ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis. Expert Opin Ther Targets 5:87–107
- Seth A, Papas TS. (1990). The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. Oncogene 5:1761–7
- Simard EP, Ward EM, Siegel R, Jemal A. (2012). Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 13:118–28
- Teng HW, Yang SH, Lin JK, et al. (2002). CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 16:1037–47
- Tseng LM, Liu CY, Chang KC, et al. (2012). CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 14:68–82
- Vaarala MH, Väisänen MR, Ristimäki A. (2010). CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29:136 . doi: 10.1186/1756-9966-29-136
- Viola JR, Rafael DF, Wagner E, et al. (2013). Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv. [Epub ahead of print]. doi: 10.1155/2013/897348
- Wang J, Li W, Li L, et al. (2011). CIP2A is overexpressed in acute myeloid leukemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 33:290–8